Towards evolutionary therapy in lung cancer: from bench to bedside

This grand round has already taken place.

Despite excellent initial responses to the powerful and specific new inhibitors of cancer driving mutations in non-small cell lung cancers like ALK or EGFR, patients inevitably experience recurrence of refractory disease- a process driven by Darwinian evolution. We seek to focus on the process of evolution itself as a targetable and rationally perturbable process. In this talk we will describe mathematical tools used to control large natural populations like those in game reserves or fisheries-termed evolutionary games- and how these can be applied to clinical oncology. We will then describe an in vitro assay we have developed to directly measure the parameters of these models for specific scenarios, and results of these measures for both ALK and EGFR mutated NSCLC. We will conclude by describing how to translate these findings and concepts to adaptive, evolutionary trial design. 

• Streams
• Additional Info
• Speakers
• Location
• Accreditation
• Disclosure

Please contact the Grand Round coordinator listed below:

Jessica Mattera
Department: Pathology Department
Phone: (631) 444-3000
Email: jessica.mattera2@stonybrookmedicine.edu